Sökning: id:"swepub:oai:DiVA.org:uu-16956" >
C-Peptide replaceme...
C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
-
Ekberg, Karin (författare)
-
- Brismar, Tom (författare)
- Karolinska Institutet
-
Johansson, Bo-Lennart (författare)
-
visa fler...
-
Lindström, Per (författare)
-
- Juntti-Berggren, Lisa (författare)
- Karolinska Institutet
-
Norrby, Anders (författare)
-
- Berne, Christian (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Endokrinologi, diabetes och metabolism
-
- Arnqvist, Hans, 1943- (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Avdelningen för medicinsk cellbiologi,Endokrin- och magtarmmedicinska kliniken US
-
- Bolinder, Jan (författare)
- Karolinska Institutet
-
- Wahren, John (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- American Diabetes Association, 2007
- 2007
- Engelska.
-
Ingår i: Diabetes Care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 30:1, s. 71-76
- Relaterad länk:
-
http://care.diabetes...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.2...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE - C-peptide replacement in animals results in amelioration of diabetes-induced functional and structural abnormalities in peripheral nerves. The present study was undertaken to examine whether C-peptide administration to patients with type 1 diabetes and peripheral neuropathy improves sensory nerve function. RESEARCH DESIGN AND METHODS - This was an exploratory, double-blinded, randomized, and placebo-controlled study with three study groups that was carried out at five centers in Sweden. C-peptide was given as a replacement dose (1.5 mg/day, divided into four subcutaneous doses) or a dose three times higher (4.5 mg/day) during 6 months. Neurological examination and neurophysiological measurements were performed before and after 6 months of treatment with C-peptide or placebo. RESULTS - The age of the 139 patients who completed the protocol was 44.2 ± 0.6 (mean ± SE) years and their duration of diabetes was 30.6 ± 0.8 years. Clinical neurological impairment (NIA) (score >7 points) of the lower extremities was present in 86% of the patients at baseline. Sensory nerve conduction velocity (SCV) was 2.6 ± 0.08 SD below body height-corrected normal values at baseline and improved similarly within the two C-peptide groups (P < 0.007). The number of patients responding with a SCV peak potential improvement >1.0 m/s was greater in C-peptide-treated patients than in those receiving placebo (P < 0.03). In the least severely affected patients (SCV < 2.5 SD below normal at baseline, n = 70) SCV improved by 1.0 m/s (P < 0.014 vs. placebo). NIA score and vibration perception both improved within the C-peptide-treated groups (P < 0.011 and P < 0.002). A1C levels (7.6 ± 0.1% at baseline) decreased slightly but similarly in C-peptide- and placebo-treated patients during the study. CONCLUSIONS - C-peptide treatment for 6 months improves sensory nerve function in early-stage type 1 diabetic neuropathy.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ekberg, Karin
-
Brismar, Tom
-
Johansson, Bo-Le ...
-
Lindström, Per
-
Juntti-Berggren, ...
-
Norrby, Anders
-
visa fler...
-
Berne, Christian
-
Arnqvist, Hans, ...
-
Bolinder, Jan
-
Wahren, John
-
visa färre...
- Artiklar i publikationen
-
Diabetes Care
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet
-
Linköpings universitet